Copyright © Inderes 2011 - present. All rights reserved.

Biohit

3.56 EUR

+0.56 %

4,890 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.56 %
+16.34 %
+26.24 %
+29.93 %
+55.46 %
+57.52 %
+111.90 %
+78.89 %
-31.54 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
54.1M EUR
Turnover
65.9K EUR
P/E (adj.) (25e)
25.67
EV/EBIT (adj.) (25e)
18.92
P/B (25e)
3.76
EV/S (25e)
3.03
Dividend yield-% (25e)
0.97 %
Coverage
Recommendation
Reduce
Target price
3.70 EUR
Updated
13.11.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 13.11.2025

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.2
2026

Annual report '25

3.6
2026

General meeting '26

5.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
This is good for the patient just by avoiding an endoscopy, as it’s not a pleasant procedure. Nordnet Nordnet Tee säästämisestä osakkeisiin & rahastoihin hauskempaa. Sijoittaminen osakkeisiin, rahastoihin ja ETF:iin ilman tarpeettomia kuluja. Tervetuloa Suomen tyytyväisimpien sijoittajien...
9 hours ago
by enska
7
Direct reference to the Finnish Limited Liability Companies Act (Osakeyhtiölaki | 624/2006 | Lainsäädäntö | Finlex) Chapter 18 Redemption of minority shares General provisions Section 1 Right and obligation to redeem A person who holds more than nine-tenths of all the shares and ...
12/5/2025, 6:37 PM
by Taavetti
5
It’s great that this year marks 20 years since Gastropanel’s market entry, so it would be high time to make it big
3 hours ago
by Junkbondking
4
I’ll open up some more content so that the information isn’t just behind links. New study: GastroPanel® safely rules out the need for gastroscopy A recently published clinical study confirms that when the GastroPanel® test result is normal, upper abdominal endoscopy, i.e., gastroscopy...
7 hours ago
by Ituhippinen
4
Of course, the patient’s symptoms, history, and risk factors influence the decision.
6 hours ago
by PaulKo
2
At least according to that press release: “Up to 90% of gastroscopies can be avoided when the GastroPanel® result is normal.” And in the CEO’s own words (in the same release), the same claim: Biohit CEO Jussi Hahtela: “The results are very clear: when the GastroPanel® result is normal...
4 hours ago
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
1
Do you assume that every test and treatment performed in hospitals is 100% accurate/successful? For example, over the past year, there have been many positive news stories from studies around the world where GastroPanel has been clearly proven to be a working solution.
4 hours ago
by Jmaksa
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.